Oral News and Research

RSS

Polio vaccination campaign targeting 72M children in 15 African countries announced; Ugandan health authorities declare polio outbreak

The WHO on Tuesday announced a mass polio immunization campaign in 15 African countries targeting a total of 72 million children, Agence France-Presse reports. "Polio has spread again in recent years with cases imported from some of the four endemic nations in Asia and Africa, mainly Nigeria, in a setback to global attempts to eradicate the crippling and sometimes lethal disease," the news service writes (10/26).

28 Oct 2010

Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH).

28 Oct 2010

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Boehringer Ingelheim Ltd. today announces that Health Canada has granted approval of PRADAX (dabigatran etexilate), an oral anticoagulant for the prevention of stroke and systemic embolism in adults with atrial fibrillation in whom anticoagulation is appropriate. PRADAX is the first innovative drug approved in Canada in more than two decades to reduce the risk of stroke in Canadians with atrial fibrillation.

28 Oct 2010

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine.

28 Oct 2010

BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA

BioDelivery Sciences International, Inc. today announced a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) which took place on September 14, 2010. At that meeting, agreement was reached on the BEMA Buprenorphine development plan for the treatment of chronic pain.

28 Oct 2010

Reuters examines development progress of microbicide gel to prevent HIV

Reuters reports that the developers of a vaginal microbicide gel containing the antiretroviral tenofovir, which has been found to reduce "HIV infections in women by 39 percent," said the FDA last week granted fast-track approval designation to the gel.

28 Oct 2010

Procter & Gamble 2010 first quarter net sales increases 2% to $20.1 billion

The Procter & Gamble Company reported first quarter diluted net earnings per share from continuing operations of $1.02 per share, an increase of five percent and above the Company’s guidance range of $0.97 to $1.01.

27 Oct 2010

Prevention, oral health literacy, rebuilding public health infrastructure are key to improving nation's oral health

The American Dental Association (ADA) said today that it welcomes an organization of the stature of the W.K. Kellogg Foundation to join the fight to improve the nation's oral health.

27 Oct 2010

Sex hormones behind increased risk of destructive periodontitis in men

Sex hormones may be the biological reason why men are at greater risk than women for destructive periodontitis, an infection of the gums, according to researchers at the University of Maryland Dental School.

27 Oct 2010

Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda

Oramed Pharmaceuticals Inc. a developer of oral drug delivery systems, announced today that its work entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," will be presented at the Tenth Annual Meeting of the Diabetes Technology Society, to be held in Bethesda, Maryland this November.

27 Oct 2010

Bivalent oral polio vaccine produces better immune response than more commonly used trivalent vaccine, study says

The bivalent oral polio vaccine (bOPV) was found to induce a significantly higher immune response than the existing trivalent oral polio vaccine (tOPV), according to a study published on Tuesday in the journal Lancet, Reuters reports.

27 Oct 2010

ARIAD prices common stock public offering

ARIAD Pharmaceuticals, Inc. announced today the pricing of an underwritten public offering of 16,000,000 shares of its common stock at $3.70 per share. The offering is expected to close on or about October 29, 2010, subject to customary closing conditions. In addition, ARIAD has granted the underwriters a 30-day option to purchase up to 2,400,000 shares of common stock to cover over-allotments, if any.

27 Oct 2010

PinPointe FootLaser receives FDA clearance for treatment of nail fungus

The podiatry practice of Mark E. Spier, DPM, announced today that the PinPointe™ FootLaser™ has received clearance from the U.S. Food and Drug Administration (FDA) for the treatment of nail fungus (onychomycosis). Dr. Spier is the first certified provider of the treatment in the Baltimore area.

26 Oct 2010

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

Infinity Pharmaceuticals, Inc. today announced that Purdue Pharmaceutical Products L.P. and its independent associated company, Mundipharma International Corporation Ltd., have exercised their right to assume worldwide development and commercialization activities for Infinity's fatty acid amide hydrolase, or FAAH, program. The decision reflects progress made in the development of Infinity's oral FAAH inhibitor, IPI-940.

26 Oct 2010

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

Agile Therapeutics announced results today from a Phase 2 clinical study of AG200-15, Agile's weekly contraceptive patch containing ethinyl estradiol (EE) in combination with levonorgestrel (LNG). According to the clinical findings, AG200-15 provides a low daily dose of estrogen equivalent to 30 micrograms EE, similar to that in low-dose, oral contraceptive (OC) pills.

26 Oct 2010

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

Biogen Idec Inc. a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its third quarter 2010 results.

26 Oct 2010

72 million children to be immunized against polio across 15 African countries

This week, Africa seizes an unprecedented chance to drive out polio when 15 countries across the continent launch a synchronized mass immunization campaign to reach 72 million children, capitalizing on gains made this year. A total of some 290 000 vaccinators have been mobilized to go door-to-door to deliver two drops of oral polio vaccine (OPV) to every child under five in areas considered at "highest risk" of polio transmission.

26 Oct 2010

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

Researchers have identified an important signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer. Their research showed that the Notch pathway and Hes1 gene play a key role in promoting the metastasis of osteosarcoma, the most common form of bone cancer in children.

26 Oct 2010

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the presentation of Phase II data from Hodgkin Lymphoma patients treated in the 1st Simon Stage cohort of the ongoing SAPHIRE study with resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, at the 8th International Symposium on Hodgkin Lymphoma in Cologne, Germany.

26 Oct 2010

Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta

Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).

26 Oct 2010

Oral News and Research

Polio vaccination campaign targeting 72M children in 15 African countries announced; Ugandan health authorities declare polio outbreak

Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA

Reuters examines development progress of microbicide gel to prevent HIV

Procter & Gamble 2010 first quarter net sales increases 2% to $20.1 billion

Prevention, oral health literacy, rebuilding public health infrastructure are key to improving nation's oral health

Sex hormones behind increased risk of destructive periodontitis in men

Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda

Bivalent oral polio vaccine produces better immune response than more commonly used trivalent vaccine, study says

ARIAD prices common stock public offering

PinPointe FootLaser receives FDA clearance for treatment of nail fungus

Purdue and Mundipharma assume worldwide development for Infinity's fatty acid amide hydrolase program

Agile presents AG200-15 contraceptive patch Phase 2 clinical study results at 66th ASRM

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

72 million children to be immunized against polio across 15 African countries

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

Sanofi-aventis commences teriflunomide Phase III study in RMS patients treated with interferon beta

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News